Sinclair Pharma Limited reported that effective at the end of the year, Doug Abel has resigned his position as Head of North America and President of Silhouette Lift, Inc., to lead a new aesthetic venture and has licensed the US sales and marketing rights to the Refine Support System from Sinclair. The company has also appointed Amber Edwards to the positions of President, Silhouette Lift, Inc., and Head of North America for Sinclair Pharma.
In her new role, Ms. Edwards will lead commercial operations and oversee the growth and expansion of the U.S. team, including an ongoing expansion of the U.S. field sales team as well as advancement of the existing line of products and pipeline into the United States and Canada. Ms. Edwards’ new role will take effect on December 1, 2018.
Ms. Edwards joins Sinclair with more than 20 years of experience in pharmaceuticals and medical devices. She most recently served as Vice President, International Strategic Marketing, at Allergan. In this role, she had strategic responsibility for the medical aesthetics franchise for all markets outside of the U.S., leading critical market launches, innovative medical education initiatives, and spearheading consumer platforms to drive expansion and acceptance of the aesthetics category. Prior to her time abroad with Allergan, Ms. Edwards was head of marketing for Allergan’s U.S. dry eye franchise, leading Restasis® and the artificial tears business past the $1 billion blockbuster milestone.
“Amber is a highly accomplished pharma executive with a long history of proven success leading major healthcare brands and franchises in both U.S. and international markets, including product launches and portfolio lifecycle management,” said Chris Spooner, Chief Executive Officer of Sinclair. “As President, U.S., she will bring continuity to Sinclair’s leadership and will be instrumental in leading our expansion and growth in this critical geographic region.”
Mr. Spooner continued, “On behalf of the Sinclair executive team, I’d like to thank Doug for his leadership over the last few years in helping us establish a presence in the United States. His commitment and expertise have been critical in building the foundation of our business and establishing a platform for our future growth. We wish him all the best as he continues onto his next venture.”
“In my new role, I’m excited to build on the progress that Sinclair has made in marketing our portfolio of differentiated, complementary aesthetic products, including our flagship product, Silhouette InstaLift,” said Ms. Edwards. “I firmly believe that the aesthetics market has reached a tipping point, with a cultural shift and new generation of consumers making interest in physician-administered treatments more acceptable than ever before. The path forward will be through more natural-looking treatments that restore lost volume and reshape for a youthful profile, and Sinclair is in the perfect position to build out a portfolio of minimally-invasive treatments to meet this aspiration.”
Sinclair’s commitment to continued U.S. expansion and growth highlights the Company’s goal of expanding global operations and becoming one of the leaders in aesthetics. In November 2018, Sinclair was acquired by Huadong Medicine Company Limited (HMC), a major Chinese pharmaceutical company that has established a leading aesthetics business in China, in order to strengthen resources and grow its aesthetic product portfolio.